BloodPressureHeartMeds.Net

Merck issues statement on GARDASIL human papillomavirus vaccine

August 01, 2017

Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS with sunitinib in 1,059 patients, treated on clinical trials, with metastatic RCC (Oral Presentation, Abstract #1006, September 26).

SUTENT is approved for gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate, as well as advanced RCC, and progressive, well-differentiated pancreatic neuroendocrine tumors (pancreatic NET) in patients with unresectable locally advanced or metastatic disease.

Axitinib

Data presentations for axitinib, an oral and selective inhibitor of VEGF 1, 2 and 3, receptors, include:

Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with PFS and blood pressure in metastatic RCC in the Phase 3 trial of axitinib vs sorafenib (AXIS trial) (Oral presentation, Abstract #7103, September 24) Time to deterioration (TTD) in patient-reported outcomes in Phase 3 AXIS trial of axitinib vs. sorafenib as second-line therapy for metastatic RCC (Poster Discussion, Abstract #3006, September 26) A randomized Phase 2 study of axitinib dose titration in patients with advanced RCC: Preliminary pharmacokinetic and ambulatory blood pressure monitoring results (Poster Presentation, Abstract #7140, September 25)

Additionally, data on the following compounds will be presented: AROMASIN (exemestane) and neratinib.

Source: Pfizer